The activation of group I metabotropic glutamate receptor (group I mGlus) has been shown to produce neuroprotective or neurotoxic effects. In this study, we investigated the effects of N-acetylcysteine (NAC), a precursor of the antioxidant glutathione, on group I mGlus activation in apoptosis of glial C6 and MN9D cell lines, and a rat model of Parkinson's disease (PD). We demonstrated that NAC protected against apoptosis through modulation of group I mGlus activity. In glial C6 cells, NAC promoted phosphorylation of ERK induced by (s)-3,5- dihydroxy-phenylglycine (DHPG), an agonist of group I mGlus. NAC enhanced the group I mGlus-mediated protection from staurosporine (STS)-induced apoptosis following DHPG treatment. Moreover, in rotenone-treated MN9D cells and PD rat model, NAC protected against group I mGlus-induced toxicity by compromising the decrease in phosphorylation of ERK, phosphorylation or expression level of TH. Furthermore, the results showed that NAC prohibited the level of ROS and oxidation of cellular GSH/GSSG (Eh) accompanied by activated group I mGlus in the experimental models. Our results suggest that NAC might act as a regulator of group I mGlus-mediated activities in both neuroprotection and neurotoxicity via reducing the oxidative stress, eventually to protect cell survival. The study also suggests that NAC might be a potential therapeutics targeting for group I mGlus activation in the treatment of PD.
References
[1]
Maiese K, Chong ZZ, Li F (2005) Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res 2: 425–446.
[2]
Pshenichkin S, Dolinska M, Klauzinska M, Luchenko V, Grajkowska E, et al. (2008) Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation-possible role as a dependence receptor. Neuropharmacology 55: 500–508.
[3]
Allen JW, Knoblach SM, Faden AI (2000) Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ 7: 470–476.
[4]
Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE (2004) Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci U S A 101: 7751–7756.
[5]
Berkeley JL, Levey AI (2003) Cell-specific extracellular signal-regulated kinase activation by multiple G protein-coupled receptor families in hippocampus. Mol Pharmacol 63: 128–135.
[6]
Thandi S, Blank JL, Challiss RA (2002) Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 83: 1139–1153.
[7]
Alonso M, Medina JH, Pozzo-Miller L (2004) ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem 11: 172–178.
[8]
Brunzell DH, Russell DS, Picciotto MR (2003) In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J Neurochem 84: 1431–1441.
[9]
Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ (2008) Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 86: 108–117.
[10]
Bi J, Jiang B, Hao S, Zhang A, Dong Y, et al. (2009) Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. Neurochem Int 54: 264–270.
[11]
Kulich SM, Chu CT (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 77: 1058–1066.
[12]
Oh-hashi K, Maruyama W, Yi H, Takahashi T, Naoi M, et al. (1999) Mitogen-activated protein kinase pathway mediates peroxynitrite- induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 263: 504–509.
[13]
Meli E, Baronti R, Pangallo M, Picca R, Moroni F, et al. (2005) Group I metabotropic glutamate receptors stimulate the activity of poly(ADP-ribose) polymerase in mammalian mGlu1-transfected cells and in cortical cell cultures. Neuropharmacology 49: 80–88.
[14]
Sagara Y, Schubert D (1998) The activation of metabotropic glutamate receptors protects nerve cells from oxidative stress. J Neurosci 18: 6662–6671.
[15]
Albasanz JL, Ros M, Martin M (1997) Characterization of metabotropic glutamate receptors in rat C6 glioma cells. Eur J Pharmacol 326: 85–91.
[16]
Choe ES, Wang JQ (2001) Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum. Neurosci Lett 313: 129–132.
[17]
Gallagher SM, Daly CA, Bear MF, Huber KM (2004) Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J Neurosci 24: 4859–4864.
[18]
Posadas I, Vellecco V, Santos P, Prieto-Lloret J, Cena V (2007) Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line. Br J Pharmacol 150: 577–585.
[19]
Zhang XD, Gillespie SK, Hersey P (2004) Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 3: 187–197.
[20]
Agari T, Yasuhara T, Matsui T, Kuramoto S, Kondo A, et al. (2008) Intrapallidal metabotropic glutamate receptor activation in a rat model of Parkinson's disease: behavioral and histological analyses. Brain Res 1203: 189–196.
[21]
Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, et al. (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24: 828–835.
[22]
Dauer W, Przedborski S (2003) Parkinson's Disease: Mechanisms and Models. Neuron 39: 889–909.
[23]
John WH, Natalie GA, Melanie HC, Edwin GK (1992) ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. Proc. Nati. Acad. Sci 89: 2365–2369.
[24]
Zhou F, Wu JY, Sun XL, Yao HH, Ding JH, et al. (2007) Iptakalim alleviates Rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia- mediated neuroinflammation. Neuropsychopharmacol 32: 2570–2580.
[25]
Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, et al. (2010) Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 17: 130–141.
[26]
Martin V, Herrera F, Garcia-Santos G, Antolin I, Rodriguez-Blanco J, et al. (2007) Signaling pathways involved in antioxidant control of glioma cell proliferation. Free Radic Biol Med 42: 1715–22.
[27]
Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, et al. (2007) Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 32: 189–195.
[28]
Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 69: 318–326.
[29]
Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58: 981–986.
[30]
Park SW, Kim SH, Park KH, Kim SD, Kim JY, et al. (2004) Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 363: 243–246.
[31]
Maiese K, Vincent AM (1999) Group I metabotropic receptors down-regulate nitric oxide induced caspase-3 activity in rat hippocampal neurons. Neurosci Lett 264: 17–20.
[32]
Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W (2007) Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol 554: 18–29.
